Cost of treatment of metastatic non-small lung cancer in Sweden, 2011-2023.

Acta Oncol · 2025 · PMC12576694 · PMID 41139898

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

This study highlights the significant cost burden of treating mNSCLC in Sweden, with an increasing trend following the introduction of the molecularly targeted and IO drugs.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.